U.S. Population Reference Values for the Myelofibrosis Symptom Assessment Form
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210727
Abstract: Background The patient experience with myelofibrosis (MF) symptoms differs throughout the disease continuum, worsening as the disease progresses. The Myelofibrosis Symptom Assessment Form v4.0 (MFSAF) is frequently used in clinical trials to assess MF symptom… read more here.
Keywords: mean difference; population; reference values; mfsaf ... See more keywords
Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5588
Abstract: Background: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by erythrocytosis that is often accompanied by fatigue, pruritus, problems with concentration, and other symptoms. At times, these symptoms can be debilitating. Rusfertide is a… read more here.
Keywords: rusfertide; rusfertide pbo; pbo; mfsaf ... See more keywords
Patient (pt) interview–based content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e23106
Abstract: e23106 Background: Pts with myelofibrosis (MF) often experience debilitating symptoms that negatively impact health-related quality of life and functioning. The MFSAF v4.0 is a 7-item questionnaire assessing the burden of MF symptoms, including fatigue, night… read more here.
Keywords: interview based; content validation; mfsaf; patient interview ... See more keywords